Alfama Overview

  • Founded
  • 2005
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 15
Employees
  • Latest Deal Type
  • M&A

Alfama General Information

Description

Developer of small-molecule drugs intended to meet the unmet medical needs. The company's small-molecule drugs cure diseases and focus on carbon monoxide releasing molecules, enabling patients to get a cure for their infectious and inflammatory diseases.

Contact Information

Website
www.alfama.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Primary Office
  • 955 Massachusetts Avenue
  • Suite 581
  • Cambridge, MA 02139
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Alfama Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 31-Dec-2017 00.000 Completed Startup
3. Early Stage VC (Series A1) 30-May-2007 00.000 00.000 000.00 Completed Startup
2. Grant $2.48M $5.36M Completed Startup
1. Early Stage VC (Series A) 07-Jul-2005 $5.36M $5.36M 000.00 Completed Startup
To view Alfama’s complete valuation and funding history, request access »

Alfama Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A1 0,000,000 00.000000 00.00 00.00 00 00.00 0.00
Series A 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view Alfama’s complete cap table history, request access »

Alfama Patents

Alfama Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
ES-2628634-T3 Carbon monoxide-ruthenium releasing molecules and uses thereof Active 21-Jul-2011 00000000
US-20140219996-A1 Ruthenium carbon monoxide releasing molecules and uses thereof Granted 21-Jul-2011 00000000 0
US-9062089-B2 Ruthenium carbon monoxide releasing molecules and uses thereof Active 21-Jul-2011 00000000 0
JP-2014520897-A Ruthenium monoxide releasing molecules and uses thereof Granted 21-Jul-2011 00000000 0
EP-2734235-A1 Ruthenium carbon monoxide releasing molecules and uses thereof Granted 21-Jul-2011 C07H5/10

Alfama Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alfama Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Beta, Sociedade de Capital de Risco Venture Capital Minority 000 0000 000000 0
Portugal Ventures Venture Capital Minority 000 0000 000000 0
To view Alfama’s complete investors history, request access »